Multiple Myeloma Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Multiple Myeloma Information Center has current, evidence-based information for you. Get the facts about multiple myeloma early detection, treatment, and survivorship, and stay up to date with ongoing multiple myeloma research that could impact your treatment decisions through our daily cancer news.
You are not alone—join us in our safe and private online community for support and inspiration, and share your experience with thousands of other individuals who have been affected by multiple myeloma. Join the discussion now to share your story and to learn how others like you have dealt with diagnosis, treatment decisions, side effects, living with metastatic disease, caregiving, and survivorship. Login or register here.
People who follow the diet and lifestyle recommendations laid out by the WCRF and the AICR have a 20 percent reduced risk of dying from cancer. Pomalyst Approved for Advanced Multiple Myeloma
The FDA has approved Pomalyst for the treatment of multiple myeloma that has progressed after treatment with other drugs. Cancer Deaths on the Decline
Overall cancer death rates are declining and cancer incidence has decreased in men and stabilized in women.
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide... Chemotherapy for Older Patients: What You Should Know About the Risk of Infection
As you may already know, chemotherapy works by attacking the rapidly dividing cells...
Multiple Myeloma Management
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer...
Multiple Myeloma Clinical Trials
06-108 – Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma (MM) Who Are Not Considered Candidates for High-Dose Chemotherapy (HDT) and Autologous Stem Cell Transplantation (SCT): VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP) (C05009)
C05009 – Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myelome Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE? (Bortezomib) for Injection, Thalidomide, and Dexamethasone (VTD) versus VELCADE? (Bortezomib) and Dexamethasone (VD) versus VELCADE? (Bortezomib), Melphalan and Prednisone (VMP)
MM03 – PHASE II TRIAL OF ARSENIC TRIOXIDE AND THALIDOMIDE IN THE TREATMENT OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA